Make your own free website on Tripod.com

Welcome to Dr. Hamid Sanatinia's Virtual Headquarters
Breast (risk category)

Home

Should we treat or not???
Performace Status
Antiemetics
Growth Factors
Calculations
Chemo Precautions
TOXICITY CRITERIA
Antidepressants
Chemoprotection
MESNA
Dexrazoxane
Radioprotectants
Hypercalcemia of malignancy
Mucositis
Neutropenic Fever
Palliative Care
Radiation Oncology
<<<<<<<<<>>>>>>>>>
ALL
AML
Anal
Bladder Cancer
Brain Cancer
Breast (risk category)
Breast (adjuvant)
Breast (metastatic)
Breast (Xeloda)
Breast (hormonal)
Breast Cancer Genetics
Carcinoid
CLL
CML
COLON CANCER
Endometrial
Esophagous
Gastric
Gestational Trophoblastic Disease
Germ Cell (Ovary)
Hairy Cell Leukemia
Head/Neck
Head/Neck: ChemoRT abstracts
Head/Neck: Larynx
Head/Neck:Nasopharyngeal
Hodgkins
Islet Cell Tumors
Kidney
Liver
LUNG, NSC
Stage III Unresectable NSC Lung Cancer
Lung, SC
Lymphoma, Aggressive
Lymphoma, AIDS
Lymphoma, Burkitts
Lymphoma, CNS
Lymphoma, Cutaneous
Lymphoma, Indolent
Lymphoma, MALT
Lymphoma, Mantle cell
Lymphoma, Mediastinal B-Cell
Lymphoma, Refractory NHL
Melanoma
Mesothelioma
Multiple Myeloma
MDS
NHL
Ovarian
Pancreas
Prostate
Prostate (Hormonal)
Rectal Cancer
Sarcoma
Sarcoma, Ewing's
Sarcoma, Osteogenic
Skeletal Metastasis
Testicular Cancer
Thymoma
Thyroid Cancer
Waldenstrom's
Unknown Primary
<<<<<<<<<>>>>>>>>>
Molecular Genetics
Oncogenes, the list!
Immunoperoxidase stains
Tumor Markers
Bleomycin
Cisplatin
Etoposide
Ifosfamide
Methotrexate
Temazolamide
Mechanism of Action
Dose Modifications (Renal)
Dose Modifications (hepatic)
MDR

Survival Rates
Risk categories for women with node-negative breast cancer
Adjuvant systemic treatment options for women with axillary node-negative breast cancer
Treatment options for women with axillary node-positive breast

8-Year Survival of Patients with Breast Cancer According to Stage:
I- 90%
II- 70%
III- 40%
IV- 10%

Risk categories for women with node-negative breast cancer
LOW RISK:
tumor size (<=1CM) AND ER or PR (positive) AND tumor grade (grade 1)
INTERMEDIATE RISK:
tumor size (1-2CM) AND ER or PR (positive) AND tumor grade (grade 1-2)
HIGH-RISK:
tumor size (>2 CM) OR ER or PR (negative) OR tumor grade (grade 2-3)

____________________________________________________
Adjuvant systemic treatment options for women with axillary node-negative breast cancer

PREMENOPAUSAL ER or PR POSITIVE
LOW RIK: no treatment or tamoxifen
INTERMEDIATE RISK: tamoxifen+chemotherapy or tamoxifen alone, or ovarian ablation, or GnRH analogue
HIGH RISK:Chemotherapy+tamoxifen or chemotherapy + ovarian ablation or GnRH analogue or chemotherapy + tamoxifen + ablation or GnRH analoguetion or GnRH analogue

PREMENOPAUSAL ER or PR NEGATIVE
HIGH RISK: Chemotherapy

POSTMENOPAUSAL ER or PR POSITIVE
LOW RIK: no treatment or tamoxifen
INTERMEDIATE RISK: tamoxifen+chemotherapy or tamoxifen alone
HIGH RISK: tamoxifen+chemotherapy or tamoxifen alone

POSTMENOPAUSAL ER or PR NEGATIVE
HIGH RISK: Chemotherapy

>70 YEARS OLD
LOW RIK: no treatment or tamoxifen
INTERMEDIATE RISK: tamoxifen+chemotherapy or tamoxifen alone
HIGH RISK: tamoxifen; chemotherapy if ER/PR negative

____________________________________________________
Adjuvant systemic treatment options for women with axillary node-positive breast cancer

PREMENOPAUSAL ER or PR POSITIVE
Chemotherapy + Tamoxifen, or chemotherapy + ovarian ablation/GnRH analogue. or chemotherapy + tamoxifen +ovarian ablation/GnRH analogue

PREMENOPAUSAL ER or PR NEGATIVE
Chemotherapy

POSTMENOPAUSAL ER or PR POSITIVE
Tamoxifen plus chemotherapy, tamoxifen alone

POSTMENOPAUSAL ER or PR NEGATIVE
Chemotherapy

>70 YEARS OLD
Tamoxifen; chemotherapy if ER/PR negative

Enter supporting content here